MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

“We are delighted to partner with Advanced Clinical for our pivotal phase III clinical trial, PARA_OA_012,” managing director ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial ...

Phase III trials aim to confirm the safety and effectiveness of groundbreaking treatments, bringing hope for new therapies to tackle often challenging medical conditions with limited therapeutic ...

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...